Introduction
============

COPD is an international health problem with a worldwide prevalence of at least 9.34/1000 in men and 7.33/1000 in women (1990 estimate) ([@b99-copd-1-289], [@b100-copd-1-289]). It is the fourth leading cause of death worldwide ([@b146-copd-1-289]). The burden of COPD is expected to increase, such that by 2020, it will be the fifth leading cause of lost disability-adjusted life years worldwide ([@b99-copd-1-289], [@b100-copd-1-289]).

The 2001 Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) guidelines recommend a step-wise approach to care as lung function declines and patients become more symptomatic with the addition of therapeutic interventions including bronchodilators (short- and long-acting), anticholinergic agents, pulmonary rehabilitation, inhaled glucocorticoids, and oxygen ([@b112-copd-1-289]). While this strategy has improved management, the only intervention that slows progression of disease is smoking cessation, as has been documented in the Lung Health Study I, EUROSCOP, the Copenhagen City Lung Study, and the ISOLDE trial ([@b23-copd-1-289]; [@b113-copd-1-289]). Additionally, while oxygen improves survival in hypoxemic patients with COPD, survival is no different from similar patients with no hypoxemia ([@b101-copd-1-289]). As a result, COPD remains a progressive, incurable illness.

Predicting survival and timing of disability in COPD is difficult. Lung function decreases with age and age is inversely proportional to survival. Decline in lung function is not always continuous. The course of COPD is punctuated by acute exacerbations with deterioration in lung function that is less likely to completely resolve as disease progresses ([@b22-copd-1-289]). Exacerbations increase in frequency as lung function declines and some individuals experience a more rapid deterioration than others. These "rapid decliners" have been identified in prospective studies but it is not clear what sets them apart ([@b51-copd-1-289]). Other variables that influence mortality include forced expiratory volume in one second (FEV~1~), nutritional status, and associated co-morbid disease ([@b93-copd-1-289]). Mortality increases as FEV~1~ declines ([@b88-copd-1-289]), although mortality is best predicted by a multifactorial staging system that includes factors in addition to FEV~1~ ([@b24-copd-1-289]). Overall, patients with COPD follow a trajectory of illness characterized by intermittent worsening followed by improvements in performance status with an overall progression towards complete disability and then death ([@b83-copd-1-289], [@b82-copd-1-289]) ([Figure 1](#f1-copd-1-289){ref-type="fig"}).

As time passes, quality of life (QOL) diminishes, most often as a result of increasing dyspnea that eventually becomes completely disabling. Conventional methods of alleviating dyspnea by modifying the disease begin to fail and it becomes more difficult to optimize comfort. Care of these patients is made all the more difficult by the challenge in identifying those that are "end-stage" and/or would derive benefit from palliative interventions.

Need for dyspnea management and palliative care
===============================================

There is increasing interest in identifying COPD patients who would benefit from palliative interventions and palliative care ([@b130-copd-1-289]; [@b49-copd-1-289]; [@b37-copd-1-289]). The studies are limited by the lack of a clear definition of "end-stage" COPD but do uncover important issues. [@b130-copd-1-289] looked at 63 patients with COPD who were over the age of 55 and had been admitted to the hospital with an exacerbation in the preceding 6 months. There were high levels of morbidity and significant functional limitations. Ninety-five percent of patients reported that breathlessness was their most significant debilitating symptom, with 60% indicating the highest severity level on the scale. Other symptoms causing disability included pain, fatigue, difficulty sleeping, and thirst. Decreased physical, social, and emotional functioning were also described. The authors concluded that COPD patients had a high burden of poorly controlled symptoms, most likely as a result of a focus on crisis intervention with management of acute exacerbations as opposed to continued improvement in baseline functioning.

Two subsequent studies looked at the care of "end-stage" COPD patients as compared with the care of patients with lung cancer. [@b49-copd-1-289] studied 50 patients over age 60 with COPD (defined as FEV~1~ \<0.75 L and at least one admission for hypercapneic respiratory failure) and 50 patients over age 60 with inoperable non-small cell lung cancer. The study assessed QOL by several measures as well as the quantity and quality of medical and social care received. All data were obtained by a single interviewer. Patients with COPD had consistently lower (ie, worse) scores on the MOS Short Form-36 Health Survey (SF-36) than patients with lung cancer on all subscales (p ≤ 0.05) with the exception of those measuring emotional and physical roles. COPD patients also scored higher (ie, worse) than lung cancer patients on the both the depression (10.18 \[SD 3.95\] vs 7.22 \[SD 5.16\], p\<0.01) and anxiety (11.44 \[SD 4.76\] vs 7.20 \[SD 5.25\], p\<0.0001) subscales of the Hospital Anxiety and Depression Scale (HADS). Finally, 82% of COPD patients were housebound, compared with 36% of those with lung cancer. Despite these findings, none of the COPD patients had received or been offered specialist palliative care ([@b49-copd-1-289]). Some methodological flaws weaken these results ([@b59-copd-1-289]). There were more females than males in the COPD group; female sex is associated with higher levels of symptomatology and lower health status ([@b141-copd-1-289]) as well as higher scores on the HADS ([@b1-copd-1-289]). Additionally, the lung cancer patients were a particularly well group whose survival exceeded the typical median survival for such patients in the UK ([@b59-copd-1-289]). Even in light of these discrepancies, the data produced by [@b49-copd-1-289] support the view that there is a need for better palliative care for patients with COPD. These data are in agreement with those of [@b130-copd-1-289] and were further supported by a later study published by [@b37-copd-1-289].

[@b37-copd-1-289] looked at the needs of patients with chronic lung disease or lung cancer in their final year of life as reported by a surrogate (relative, friend, or caregiver). Patients with COPD had troublesome symptoms, including pain, cough, anorexia, mouth problems, and insomnia. Breathlessness was most common, with 94% of respondents reporting this symptom during the final year of life and 76% rating it as "very distressing." This contrasts with the lung cancer patients, 78% of whom reported breathlessness (p\<0.001) with 60% describing it as "very distressing" (p=0.024). COPD patients had significantly more frequent (p\<0.001) and severe (p\<0.024) breathlessness than the lung cancer group. Similar to the findings of [@b49-copd-1-289], patients with lung cancer in the [@b37-copd-1-289] study were more likely to have received hospice care (30%) as compared with those with COPD (0%, p\<0.001).

Together, these data highlight that the symptoms of patients with COPD are at least as severe as those of patients with lung cancer and that these patients would benefit from better symptom management, particularly in the area of dyspnea. Despite the degree of symptomatology, COPD patients less frequently access palliative care.

Definition and mechanisms of dyspnea
====================================

Dyspnea is a symptom that is difficult to understand and difficult to define, for both physicians and patients. The experience of dyspnea is the combination of a sensation involving activation of neural pathways and a perception on the part of the patient ([@b7-copd-1-289]). Descriptions of dyspnea vary widely and depend, at least in part, on a patient's underlying disease, ethnic--racial background, previous experiences, and emotional state. In an attempt to incorporate each of these ideas, an American Thoracic Society consensus panel proposed that dyspnea is "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity. The experience derives from interactions among multiple physiological, psychological, social, and environmental factors, and may induce secondary physiological and behavioral responses" ([@b7-copd-1-289] p 322).

The pathophysiological mechanisms that govern the development of dyspnea are poorly understood. Dyspnea seemingly results from a mismatch of respiratory motor activity and incoming afferent activity, including information from chemo-, vagal, mechano-, pulmonary stretch, and muscle receptors ([@b7-copd-1-289]). The interaction between these individual components is only starting to be understood and there are clearly situations that cannot be defined by looking at only these factors. For example, increases in P~a~CO~2~ plus decreases in P~a~O~2~ and/or pH detected by peripheral chemoreceptors result in dyspnea. However, not all patients with abnormal blood gases experience dyspnea and many dyspneic patients have normal blood gases ([@b96-copd-1-289]; [@b137-copd-1-289]; [@b66-copd-1-289]).

Researchers have tried to define the key parameters of breathlessness. Fifteen years ago, Simon and colleagues tried to look at correlates of dyspnea with underlying induced pathophysiology in normal volunteers ([@b128-copd-1-289]), and in disease pathophysiology in people with established single causes of dyspnea ([@b127-copd-1-289]). There were some clusters defined. A decade later, that idea was further developed by [@b57-copd-1-289] in their work which defined three key domains of breathlessness: depth and frequency of breathing, perceived urge of need to breathe, and difficulty breathing and phase of respiration.

Goals of palliative interventions for intractable dyspnea: relief of breathlessness and improving function
==========================================================================================================

Patients often complain of dyspnea that seems out of proportion to apparent physical disability or functional impairment. It can be difficult to care for these patients as the usual dictum to treat the dyspnea by treating the underlying disease cannot guide therapy. There is also a substantial -- and growing -- population of patients whose COPD has been maximally treated but who are still breathless. Patients whose dyspnea cannot be alleviated through further treatment of their COPD have intractable dyspnea or refractory dyspnea ([@b3-copd-1-289]).

There are palliative options that can improve symptoms and QOL for COPD patients with intractable dyspnea ([Figure 2](#f2-copd-1-289){ref-type="fig"}). The purpose of this review is to outline these options, discuss the data behind them, and provide practical guidance. Incorporating this information into clinical practice first requires that the goals of therapy are clearly articulated. We assume here that extending survival is not the primary goal of therapy. Palliative interventions should not reduce life expectancy, but can be beneficial even when they do not extend survival. The therapeutic interventions will therefore be examined in terms of their impact on relief of the sensation of breathlessness and/or their impact on functional status.

Oxygen therapy
==============

Home oxygen therapy is commonly prescribed for patients with severe COPD. Two randomized controlled trials, one by the Medical Research Council Working Party ([@b97-copd-1-289]) and the other by the Nocturnal Oxygen Therapy Trial Group (NOTT) ([@b104-copd-1-289]), demonstrated that long-term oxygen therapy (LTOT) prolongs survival in COPD patients with hypoxemia (P~a~O~2~ \<55 mmHg). LTOT oxygen is administered at home for at least 12--15 hours per day. In the NOTT trial, supplemental criteria for the use of LTOT in moderately hypoxemic patients (P~a~O~2~ 55--59 mmHg) included pulmonary hypertension, cor pulmonale, and secondary polycythemia (hematocrit ≥ 55%). These two studies form the basis on which LTOT is funded by third-party payers for the management of hypoxemic patients worldwide. The goal is prolonging survival. The studies do not focus on symptomatic treatment of dyspnea, improved function in activities of daily living, and QOL outcomes, nor do they guide treatment of patients with disabling dyspnea who are not hypoxemic.

Palliative oxygen is prescribed when the primary goal is relief of breathlessness. In this setting the data are less clear. [@b84-copd-1-289] examined the effects of palliative oxygen in non-hypoxemic patients with severe COPD. The effect of medical air vs oxygen on exercise performance and QOL was examined in a 12-week, double-blind, randomized crossover study involving 26 patients with severe COPD, mean resting P~a~O~2~ 69 mmHg (range 58--82 mmHg), and exertional dyspnea severe enough to interfere with daily activities. There were small, statistically significant (p\<0.05) increases in 6-minute walk distance with oxygen. Both oxygen and medical air improved QOL from baseline but did not affect the sensation of breathlessness. The authors concluded that there was little evidence to support prescription of home oxygen for COPD patients with only mild hypoxemia.

[@b16-copd-1-289] systematically reviewed the published English-language literature through 2003 regarding the use of palliative oxygen for the management of breathlessness in cancer, COPD, and heart failure. They focused on studies in which breathlessness was measured by intensity scales such as the visual analog scale (VAS) or Borg scales. Studies involving the use of supplemental oxygen in patients with COPD were divided as follows: 1) those investigating the use of oxygen at rest; 2) those investigating the use of oxygen before, during and after exercise (ie, "short burst" oxygen therapy); and 3) those investigating LTOT where breathlessness was an outcome in addition to survival. A complete list of the studies included is provided at the end of this article.

Most of the studies were small (range 5--50 patients) and poorly controlled. The results were inconsistent and remarkably patient dependent. The authors concluded that oxygen at rest may be one part of a palliative treatment plan for the care of patients with COPD, but that it should be used only after an "n of 1" assessment as described by [@b19-copd-1-289]. The goal of the "n of 1" individualized patient trial is to assess the impact of the oxygen in terms of both breathlessness and personal QOL. The recommendations for "short burst" oxygen were similar, reflecting the potential for some patients to benefit. For example, one study demonstrated great relief of dyspnea with oxygen for some participants, although the cumulative results for all patients in the trial were not statistically significant ([@b14-copd-1-289]). Another study showed that dyspnea before and after exertion in patients with COPD could be relieved ([@b67-copd-1-289]). Ambulatory oxygen therapy was recommended for those that desaturated on exercise but its continuous use was not as clear cut. Again, the impact of oxygen needed to be assessed on an individual basis ([@b35-copd-1-289]). Even those who appeared to derive short-term benefit may not realize sustained benefit in the long-term and/or may not wish to continue therapy ([@b35-copd-1-289]). Oxygen therapy is not without burden; people may have a sense of being tied to a machine, develop anxiety about power supply, and limit excursions outside the house.

Despite a lack of convincing evidence for benefit, palliative oxygen for the management of breathlessness is commonly prescribed. In a recently reported email survey of all 648 registered palliative care specialists and respiratory physicians in Australia and New Zealand ([@b2-copd-1-289]), 58% of the 214 respondents (69% of palliative medicine clinicians and 48% of respiratory physicians surveyed) reported a belief that palliative oxygen is beneficial and 65% of respondents cited intractable dyspnea as the most common reason for prescription. Canadian clinicians reported similar convictions ([@b136-copd-1-289]), with over 40% of patients receiving LTOT not meeting current guidelines ([@b55-copd-1-289]). There is clearly a need for a definitive randomized trial. We are members of an international collaborative investigating the role of palliative oxygen vs medical air for the relief of breathlessness in patients with intractable dyspnea and P~a~O~2~ ≥ 55 mmHg in a definitive, multi-center, randomized, double-blind controlled trial.

Until these data become available, current evidence suggests that it is reasonable to prescribe this therapy on a case by case basis. Our current clinical standard for those patients who do not enroll in the trial and do not meet criteria for LTOT is to first establish the goals of therapy in terms of relief of dyspnea, improvement in function, and improvement in QOL. Whenever possible we conduct a blinded "n of 1" trial with oxygen vs air at 2 L/min. A respiratory therapist or nurse administers the gas, randomly choosing oxygen or air without revealing the assignment to the clinician or patient. For practical reasons the gas is administered for 15 minutes only. The patient undergoes a 5-minute wash-out period and then the other gas is administered. If access to medical air is not available, the test can be conducted using a fan as the comparison, although it will not be blinded. Dyspnea is scored on a VAS or numerical rating scale (NRS). If function is a major concern, we conduct a baseline exertional test consistent with the patient's best functional status (ie, shuttle test \[[@b13-copd-1-289]\], walking 3 m, reading a paragraph). The same functional test is repeated after 10 minutes on each gas. Unblinded results are reported to the clinician and patient. If the patient has superior results on oxygen, a prescription for palliative oxygen is written after a careful discussion about the funding for oxygen in the relevant health system. If air is superior, a fan is prescribed. If both are equally helpful, then the patient is given the option to use whichever he/she prefers. If oxygen is prescribed, the patient is then asked to evaluate QOL improvements and limitations related to the therapy over the next week to ascertain if the intervention should be continued.

Pharmacological interventions
=============================

There has been a great deal of interest in treating refractory dyspnea with non-specific drug therapies aimed at altering the perception of dyspnea ([@b20-copd-1-289]). Investigators have looked at oral, parenteral, and inhaled opioids, psychotropic drugs, inhaled furosemide, and Heliox. A list of references for each of these interventions is provided at the end of this article.

Oral and parenteral opioids
---------------------------

The use of opioids in the treatment of refractory breathlessness has been the subject of investigation for many years and remains controversial. Most of this revolves around safety concerns (predominantly respiratory depression) amidst the perception of inadequate evidence for the efficacy of opioids in relieving breathlessness in COPD ([@b112-copd-1-289]; [@b28-copd-1-289])

The mechanism of action of opioids is poorly understood and these agents may act centrally, peripherally, or by reducing anxiety ([@b75-copd-1-289]). It is well known that opioids reduce ventilatory response to carbon dioxide ([@b36-copd-1-289]), hypoxia ([@b144-copd-1-289]; [@b122-copd-1-289]), inspiratory flow-resistive loading ([@b72-copd-1-289]), and exercise ([@b121-copd-1-289]). Additionally, it is known that morphine decreases oxygen consumption both at rest and with exercise in healthy individuals ([@b121-copd-1-289]). These observations led to the evaluation of oral opioids in individuals with breathlessness due to chronic airway obstruction. Most of the initial studies conducted prior to 1998 only included normocapneic individuals because of concern over respiratory depression. The studies were small (7--19 patients), used several different opioids (including dihydrocodeine, codeine, diamorphine, morphine, and sustained-release morphine) in a variety of doses, and produced conflicting results. Additionally, most of the studies were primarily interested in exercise tolerance as opposed to relief of the sensation of breathlessness and only one study by [@b114-copd-1-289] assessed QOL as measured by the Chronic Respiratory Disease Questionnaire (CRQ).

Two early studies with dihydrocodeine demonstrated decreased breathlessness with exercise as measured by VAS as well as increased exercise tolerance as measured by treadmill or pedometer in the absence of significant adverse effects ([@b152-copd-1-289]; [@b64-copd-1-289]). However, these early reports were followed by two negative studies that demonstrated significant adverse effects and raised the issue of safety ([@b116-copd-1-289]; [@b40-copd-1-289]).

[@b63-copd-1-289] systematically reviewed all data on the use of opioids through 2001 in an attempt to evaluate the evidence as a whole. In their assessment of oral and parenteral opioids, they included eight studies that evaluated oral morphine, as well as one study that evaluated subcutaneous morphine. Seven of the nine studies were of patients with COPD. Meta-analysis demonstrated a highly statistically significant effect of oral and parenteral opioids on the sensation of breathlessness (overall pooled effect size −0.31, 95% confidence internval \[CI\] −0.50 to −0.13, p=0.0008). Exercise tolerance was a secondary outcome. Meta-analysis demonstrated a trend towards an improved effect on exercise tolerance, but the CI crossed zero (−0.20, 95% CI −0.42 to +0.03, p not stated). The [@b114-copd-1-289] study found no difference in QOL between treatment and placebo. [@b63-copd-1-289] concluded that there was a definite and highly statistically significant effect of oral or parenteral opioids on the sensation of breathlessness but that the clinical effect was relatively small (approximately 8 mm on a 100 mm VAS with baseline levels of dyspnea of 50 mm). They gave several reasons for this small effect, including that the opioid doses were often small, doses were not titrated, dosing intervals were long, and single dose studies would not have achieved steady state. Additionally, their evaluation of the data did not suggest that the use of opioids was associated with changes in arterial blood gas measurements or oxygen saturation.

Following the [@b63-copd-1-289] systematic review, [@b3-copd-1-289] published results of a trial using oral morphine in opioid-naïve adults with refractory dyspnea. Forty-eight outpatients with refractory dyspnea despite optimal management were enrolled in an adequately powered 8-day randomized, double-blind, crossover study in which they received either 20 mg oral morphine sulfate or placebo. The morphine product used was a 24-hour sustained-release preparation. The primary outcome was the sensation of breathlessness measured on a 100 mm VAS; exercise tolerance was not measured. While participants were not restricted to those with COPD, 88% had COPD as the predominant cause of dyspnea. Participants were elderly (mean age 76, standard deviation \[SD\] 5) and 71% were on oxygen. The mean baseline morning dyspnea score was 43 (SD 26). In an intention to treat analysis, there was a significant decrease in dyspnea with morphine, with mean improvements in dyspnea intensity of 6.6 mm in the morning (p=0.011) and 9.5 mm in the evening (p=0.006). Relative improvement over baseline dyspnea was 15%--22%. These results were similar to the estimate of efficacy for oral and parenteral opioids generated by [@b63-copd-1-289]. Morphine did not depress the respiratory rate (RR; mean RR for morphine vs placebo = 20 \[SD 5\] vs 21 \[SD 4\], p=0.143) and no episodes of severe sedation or obtundation were recorded. The main side-effect was constipation (9 vs 1, p=0.021), but neither treatment caused more vomiting, confusion, sedation, or appetite suppression. Those who received morphine also described better sleep at night (p=0.039) despite the fact that the medication was administered each morning. We concluded that oral sustained-release morphine could provide relief to patients with refractory breathlessness, even for patients who were elderly, had COPD, and were not previously receiving background opioids. We do caution, however, that this was not a safety study and was not powered to detect infrequent significant side-effects, so these agents should be used with care.

Current data do not clarify the ideal dose of morphine, the additive effect of opioids, whether all opioids provide equal effect, or whether the effect would be as substantial in diseases other than COPD. We used a 20-mg dose of morphine as that was the lowest dose once daily sustained-release product available to us at the time of study design. A dose ranging study exploring 10--30 mg sustained-release morphine is ongoing. This study will report on long-term effectiveness and will also clarify whether there is an additional benefit to increasing the dose sequentially. A study to evaluate additive effect of additional medication in opioid-tolerant patients is also planned. In the [@b63-copd-1-289] meta-analysis, all of the studies of oral and parenteral opioids had an effect size in favor of opioids except the two studies of diamorphine. This suggests that opioids have a beneficial effect but that all opioids are not the same. A study of morphine vs oxycodone is also planned. Once adequate data are available, sub-group analyses considering COPD vs other causes of dyspnea will be conducted.

In practise, we prescribe oral morphine for COPD patients with refractory dyspnea. When the patient is opioid-naïve, we start with a 20-mg, once-daily, sustained-release morphine preparation if the drug is available and the patient does not have a contraindication to morphine. When not available, we start with the 15-mg, twice-daily, long-acting morphine product, initially prescribing it once a day and increasing to twice daily after 5--7 days if the patient tolerates the medication and has residual breathlessness. When the patient has a contraindication to morphine, we choose long-acting oxycodone starting at 10 mg once a day and increase to twice a day after 5--7 days as tolerated and needed. We have also used hydromorphone dosed around the clock in analgesic doses equal to 20--30 mg of morphine. We avoid starting with the 25-μg fentanyl transdermal patch as this provides over 80 morphine equivalents per day. If an opioid-tolerant patient is already on a regular dose of morphine or another opioid, we sequentially increase the opioid by 20% of the total daily dose every 3--5 days until the breathlessness is relieved or side-effects occur ([@b18-copd-1-289]).

Nebulized opioids
-----------------

The role of nebulized opioids in the management of refractory dyspnea has also been studied. The mechanism by which these agents may act is currently unclear but it has been proposed that there may be a direct local effect on peripheral neural receptors in small airways. Much like the data with oral opioids, the studies are small and the results inconsistent. However, on the whole, the majority of studies failed to demonstrate a benefit, as reported by [@b63-copd-1-289] in their meta-analysis. At this point, we do not feel that there is adequate evidence to support the use of nebulized opioids in the treatment of refractory breathlessness. Since the size of nebulized droplets is crucial for the activity of inhaled opioids, in the future, newer methods of microdroplet delivery of opioids may result in rapid systemic effects and improved efficacy of this method of drug delivery.

Psychotropic drugs
------------------

Use of psychotropic agents including anxiolytics, phenothiazines, and selective serotonin reuptake inhibitors (SSRIs) for the treatment of refractory dyspnea has received some attention based on the observation that there is often a large psychological component to dyspnea and that anxiety significantly contributes to functional impairment in COPD ([@b68-copd-1-289]). Diazepam was initially reported to be beneficial by [@b95-copd-1-289] when they published the results of an exploratory study in four patients. However, these results could not be replicated in two subsequent studies ([@b150-copd-1-289]; [@b125-copd-1-289]) which also raised the issue of safety. Several other investigators chose to re-look at the use of benzodiazepines but with alprazolam, a shorter-acting and potentially less-sedating medication. In one controlled study ([@b87-copd-1-289]), the investigators found no improvement in breathlessness. However, a benefit was found in a subsequent single case report ([@b53-copd-1-289]).

### Anxiolytics

Buspirone, a serotonergic anxiolytic agent, has been shown to be a respiratory stimulant in animals ([@b47-copd-1-289]; [@b94-copd-1-289]). Two small studies ([@b6-copd-1-289]; [@b129-copd-1-289]) evaluated the effects of buspirone on breathlessness, exercise tolerance, and anxiety in patients with severe COPD. These studies included slightly different patient populations in that [@b129-copd-1-289] required baseline anxiety as measured by the Speilberger State-Trait Anxiety Inventory Scale (STAI) for study enrollment and [@b6-copd-1-289] did not require any baseline anxiety assessment. The results of the studies conflicted with those of the [@b6-copd-1-289] study documenting improvement in all three domains and the other study finding no difference.

Taken together, these data, while inconsistent, suggest that there may be a role for anxiolytic agents in *selected* patients with refractory dyspnea. Further studies are needed. In practise, we perform "n of 1" trials for patients where we plan to use these agents, carefully monitoring for benefit in terms of relief of the sensation of breathlessness and improvement in function without overwhelming adverse effects. When we do not have identical appearing placebos available, we conduct single-sided "n of 1" trials carefully documenting outcomes to be reviewed by both clinician and patient.

### Phenothiazines

There are also limited, conflicting data on the use of phenothiazines. One early study comparing diazepam and promethazine reported increased exercise tolerance and decreased breathlessness with promethazine ([@b150-copd-1-289]) but these results were not supported by a subsequent study ([@b116-copd-1-289]). Additionally, the [@b116-copd-1-289] study raised concerns about side-effects, including increases in P~a~CO~2~ and drowsiness. [@b80-copd-1-289] evaluated both promethazine and prochlorperazine in combination with morphine in a double-blind, placebo-controlled study that included seven male patients with severe COPD (mean FEV~1~ 0.99 L \[SD 0.30\]). The authors found that treatment with morphine and promethazine in combination increased exercise tolerance compared with placebo (mean increase in workload of 10 W \[SD 6.3\] vs 1.4 W \[SD 6.9\], p\<0.05). Morphine and prochlorperazine had an intermediate effect (mean increase in workload of 6.4 W \[SD 6.3\]; p not reported). The cognitive effects of both combinations were also assessed. Morphine and prochlorperazine had a large negative effect on patients' mental status while morphine and promethazine produced effects no different from placebo or morphine alone. The authors suggested that the increased exercise tolerance seen with the combination of morphine and promethazine was due to a decreased level of dyspnea at a given workload despite the fact that there was no significant difference in Borg scores. Available data, therefore, do not support the routine use of phenothiazines in the management of refractory dyspnea, referring to the beneficial effect of morphine instead.

### SSRIs

In recent years, there has been interest in the use of SSRIs in the treatment of patients with COPD and breathlessness. A pilot study by [@b111-copd-1-289] reported that six patients (three of whom had psychiatric disorders) felt better after 6 weeks of sertraline, suggesting that further study was warranted. [@b131-copd-1-289] reported a case series of seven patients with obstructive lung disease treated with sertraline by their pulmonologists. All patients were evaluated by a psychiatrist, one in a prospective fashion using the Structured Clinical Interview for the DSM-III-R and the other six retrospectively with modules for depression, dysthymia, panic, agoraphobia, and generalized anxiety disorder (GAD). Four of the seven patients did not meet criteria for a psychiatric diagnosis although several experienced panic and/or anxiety during episodes of dyspnea. Of the remaining three patients, one met criteria for panic disorder with agoraphobia, one for both dysthymia and GAD, and one for major depression. All patients reported a "decrease" in breathlessness and several also reported "improvements" in exercise tolerance. There were, however, no formal measures performed. It is not clear whether SSRIs improve dyspnea and exercise tolerance by relieving anxiety symptoms or by direct effects on respiration. Many patients with dyspnea out of proportion to their pulmonary compromise experience depression and/or anxiety and there are data to suggest that treatment of these symptoms relieves dyspnea ([@b21-copd-1-289]). However, there are also animal data suggesting that serotonin acts at the level of the brainstem respiratory center and it may be this action that affects the sensation of dyspnea ([@b98-copd-1-289]). There have been no subsequent studies of SSRIs and currently there is no substantive evidence on which to recommend their use in COPD patients with refractory dyspnea in the absence of an underlying psychiatric indication. This is an important area for further study. In patients where there is concern for an underlying psychiatric disorder (eg, anxiety, depression), there should be a concerted effort to confirm the diagnosis and initiate effective therapy.

Emerging data
-------------

### Inhaled furosemide

There are two additional interventions currently under investigation. Inhaled furosemide has been studied in healthy subjects ([@b102-copd-1-289]) and in patients with COPD ([@b109-copd-1-289]). The rationale behind the use of furosemide includes its inhibitory effect on the cough response induced by low chloride content solutions ([@b142-copd-1-289]) and a preventive effect of furosemide on bronchoconstriction in asthma ([@b12-copd-1-289], [@b11-copd-1-289]; [@b118-copd-1-289]). Inhaled furosemide may also act indirectly on vagally mediated sensory nerve ending in airway epithelium ([@b26-copd-1-289]). In healthy subjects, inhaled furosemide has prolonged breathholding time and the period of no respiratory sensation and has also slowed the development of discomfort during loaded breathing ([@b102-copd-1-289]). Does inhaled furosemide have a role in the palliation of refractory dyspnea? A randomized study evaluated the effects of inhaled furosemide vs placebo in exercise-induced dyspnea (as assessed by VAS) in 19 patients with moderate to severe COPD (FEV~1~ \<70%) and moderate-to-severe chronic breathlessness ([@b109-copd-1-289]). Mean dyspnea VAS scores after exercise were lower after inhalation of furosemide (34mm \[SD 25\] vs 42 \[SD 24\], p=0.014). Exercise-related FEV~1~ and FVC also improved after furosemide inhalation (p=0.038 and 0.005, respectively) but not after placebo. Interestingly, no increase in exercise endurance time was noted. Both this study and the study by [@b102-copd-1-289] suggest that inhaled furosemide deserves further investigation in the relief of refractory breathlessness.

### Heliox28

A second agent that may have a role in the therapy of refractory breathlessness is Heliox28, a helium--oxygen mixture containing 72% helium and 28% oxygen. A Phase II crossover study assessed the palliative role of Heliox28 in 12 lung cancer patients with refractory dyspnea ([@b5-copd-1-289]). Breathlessness during 6-minute walk test was evaluated while patients were breathing Heliox28, 28% oxygen, or medical air. The VAS measurements were significantly lower when comparing Heliox28 with medical air (40.2% \[SD 4.8\] vs 59.3% \[SD 5.3\], p\<0.05) but there was no significant difference between Heliox28 and oxygen (47.0% \[SD 5.6\]) or between oxygen and medical air. There were also no significant differences in Borg scores. Patients walked farther breathing Heliox28 than breathing oxygen (214.2 m \[SD 9.6\] vs 174.6 m \[SD 11.2\], p\<0.05) or medical air (128.8 m \[SD 10.3\], p\<0.0001). The use of Heliox28 in the management of COPD has been explored ([@b52-copd-1-289]; [@b60-copd-1-289]; [@b61-copd-1-289]) but there are no studies evaluating its use in patients with COPD and refractory dyspnea. The results obtained by [@b5-copd-1-289] suggest that further investigation of Heliox28 in the therapy of COPD patients with refractory dyspnea may be warranted. Issues of cost and feasibility would need to be considered in any such investigation.

Non-pharmacological interventions
=================================

Pulmonary rehabilitation
------------------------

In 1994, "pulmonary rehabilitation" was defined by the National Institutes of Health Workshop on Pulmonary Rehabilitation Research as "a multidimensional continuum of services directed to persons with pulmonary disease and their families, usually by an interdisciplinary team of specialists, with the goal of achieving and maintaining the individual's maximum level of independence and functioning in the community" ([@b44-copd-1-289] p 826). It is a well-established component of the care of COPD patients that is included in the recommendations of most COPD care guidelines, and there have been numerous studies demonstrating its value in reducing dyspnea, improving QOL, and increasing independence--exercise capacity ([@b73-copd-1-289]; [@b54-copd-1-289]). There is also an evidence-based guideline examining its scientific basis ([@b4-copd-1-289]). Pulmonary rehabilitation is typically introduced early in the illness trajectory so, while it certainly has a role in the care of patients with advanced COPD, a detailed exploration of the data supporting its use is beyond the scope of this review.

Nutrition
---------

Malnutrition is not uncommon in patients with COPD and weight loss can become particularly severe as the disease advances. Consequences of this loss include weakness of inspiratory and expiratory muscles which can lead to impaired lung function ([@b147-copd-1-289]). Studies have demonstrated a link between malnutrition and impaired pulmonary status ([@b120-copd-1-289]) as well as with increased mortality ([@b148-copd-1-289]). It therefore stands to reason that nutritional support would constitute a simple, effective intervention in the management of patients with severe COPD. The data, however, do not support this idea.

[@b43-copd-1-289] performed a meta-analysis of eleven randomized, controlled trials looking at the effects of nutritional supplementation in patients with severe COPD. All studies evaluated the use of liquid oral supplements, including Pulmocare^®^ (Ross Laboratories, Columbus, OH, USA), Build-up^®^ (Nestle, Croydon, Surrey, UK), Sustacal^®^ (Mead Johnson Nutritionals, Bristol Myers Squibb, New York, NY, USA), Isocal^®^ (Mead Johnson Nutritionals, Bristol Myers Squibb, NY, NY, USA), and Respifor^®^ (Nutricia, Zoetermeer, Netherlands). [@b43-copd-1-289] identified no significant effect on any outcome variable, including anthropomorphic measures, pulmonary function, respiratory muscle strength, functional exercise capacity, and health-related QOL. Because only 3 ([@b38-copd-1-289];[@b110-copd-1-289];[@b135-copd-1-289]) of the 11 studies evaluated QOL or dyspnea, it is difficult to draw conclusions regarding the effect of nutrition on outcomes most important to patients with end-stage COPD who require palliation. A well-designed clinical trial of nutritional supplementation in end-stage COPD patients with dyspnea and reduced QOL would be useful to assess the effects of this simple intervention.

Psychosocial support
--------------------

Providing support is a fundamental part of caring for any patient with chronic illness, but it becomes more important as patients begin to decline and experience more functional limitations. Patients often need help coping with their illness and the changes occurring in their lives. At the same time, relatives and family members may require support as relationships and family roles change as a result of disease progression and increasing symptom burden ([@b75-copd-1-289]).

There are several qualitative studies that highlight the specific need for support of those caring for individuals with breathlessness. [@b15-copd-1-289] sought to investigate the experience of living with breathlessness both in patients with cancer or COPD and in those individuals providing informal care. The investigators interviewed 10 COPD patients and their caregivers in their homes; 30% of interviews were conducted separately. Six of the patients were male; they were all Caucasian and ranged in age from 51 to 80 years (mean = 70 years). The study found that many caregivers found taking care of a breathless person to be "pre-occupying, restricting, and a major cause of anxiety" ([@b15-copd-1-289] p 341). Anxiety was noted to be particularly bad a night and several caregivers described spending time listening to their spouse breathing. The investigators concluded that clinicians must not forget about the needs of their patients' families and that patients with disabling symptoms are often best cared for using a multidisciplinary approach. A similar study described the experiences of 10 patients with COPD and their caregivers ([@b124-copd-1-289]). The caregivers were married to the patient in seven of the 10 cases and ranged in age from 60 to 93 years (mean 72 years). They expressed losses similar to those of the patients and felt burdened by the multiple roles that they were forced to fulfill. There was also a sense that it was not fair that the illness affected both patient and caregiver and this often contributed to tension in the relationships.

There are no specific guidelines available regarding specific support for either patients or their informal caregivers. Clinicians caring for these patients must be conscious of the potential need for increased support as well as responsive to patient--family concerns when they arise. To date there have been no reports of systematic evaluation of isolated behavioral or psychosocial interventions for COPD patients with intractable dyspnea. This is an important area for future study.

Breathing techniques
--------------------

Several controlled breathing techniques including positioning and pursed lip breathing (PLB) are useful in the management of breathlessness. The most commonly used position is one in which the patient leans forward and supports his/her weight with the arms--upper body. This serves to increase abdominal pressure and may improve respiratory muscle function ([@b7-copd-1-289]). Use of the leaning forward position has also been reported to improve inspiratory muscle strength ([@b108-copd-1-289]) and diaphragmatic function ([@b126-copd-1-289]), reduce the use of accessory muscles, and decrease abdominal breathing ([@b9-copd-1-289]; [@b8-copd-1-289]; [@b126-copd-1-289]). PLB involves inhalation through the nose followed by a slow exhalation, usually 4--6 seconds, through pursed lips. It has been shown to decrease air trapping by stenting the airways and preventing dynamic airway collapse ([@b140-copd-1-289]) and often helps to avert panic attacks that accompany severe breathlessness ([@b85-copd-1-289]). Unfortunately, despite studies demonstrating the benefit of these techniques in relieving dyspnea, the results in practice are variable ([@b7-copd-1-289]). In practise, instruction in positioning and PLB is provided to all of our patients with dyspnea, and the skills reviewed during subsequent clinic visits.

Breathlessness clinics
----------------------

"Breathlessness clinics" are another potential intervention for dyspneic patients with advanced COPD. Nurse practitioners who run these clinics lead weekly sessions that focus on counseling, breathing re-training, relaxation, and coping--adaptation strategies for dealing with breathlessness. The "breathlessness clinic" model combines education and psychosocial support, and has thus far focused on patients with lung cancer.

The initial pilot study demonstrating benefit of these clinics was published in 1996 ([@b27-copd-1-289]). It involved 34 lung cancer patients with breathlessness randomized to the nursing intervention or control. The intervention group attended weekly 1-hour sessions for 3--6 weeks. During these sessions, the nurse practitioner assessed patients' breathlessness, disease, and feelings. He/she gave advice and support about managing breathlessness, including activity pacing, as well as education on breathing and relaxation techniques. The control group was encouraged to talk about their disease but received no counseling or breathing training. Outcomes were assessed at baseline, one month and three months by three separate VAS scales, the Functional Capacity Scale, and the HADS. The study stopped recruiting at 34 patients at the request of the clinic staff who noted benefit in the intervention group. Despite the small number of participants and the loss of 14 patients, leaving only 20 patients for analysis, 3 months after study entry the intervention group saw significant improvements in worst breathlessness (p=0.02), distress caused by breathlessness (p=0.02), and functional capacity (p=0.03). Symptoms in the control group either remained static or worsened over the course of the study.

Two subsequent studies ([@b17-copd-1-289]; [@b58-copd-1-289]) have further validated this concept. In a multicenter study involving 119 patients, [@b17-copd-1-289] found similar improvements in breathlessness at best (p=0.03), performance status (p=0.02), depression (p=0.02), physical symptoms (p=0.04), and activity (ie, climbing stairs, walking outdoors, and going shopping, p=0.05). A smaller study by [@b58-copd-1-289] of 30 breathless patients with lung cancer also demonstrated improvements. The authors saw a decrease in frequency of respiratory symptoms (p\<0.001) as well as an improvement in functional capacity (p\<0.001) and QOL scores, with the greatest improvement in "patients' ability to do what they want" (p=0.001) and in overall QOL (0.004). Breathlessness scores were improved with significant reductions in VAS scores for breathing at best (median reduction = 1, p=0.001), breathing at worst (median reduction = 3, p\<0.001) and distress caused by breathing (median reduction = 4, p\<0.001). Qualitative data demonstrated the value of the intervention on patient's adjustment to their cancer diagnosis as well as their sense of well-being.

These three studies ([@b27-copd-1-289]; [@b17-copd-1-289]; [@b58-copd-1-289]) suggest a role for a nursing intervention incorporating psychosocial support and education in the care of breathless patients with lung cancer. There no studies evaluating such an intervention in patients with end-stage COPD, though this is a population that would likely derive similar benefit. Practically, patients with lung cancer and COPD may be referred to a "breathlessness clinic" when such a specialty clinic is available. However, these types of tertiary referral clinics are often not the ideal setting to see a sick patient and his/her family on a regular basis, so continued follow-up by the referring physician with attention to continued symptom management is required. Future goals should focus on evaluating this model in other diseases and developing sustainable models that can be rolled out worldwide.

Conclusions and future directions
=================================

COPD is a common disease with a course that deteriorates in a relentless fashion until culminating in severe functional limitation and symptom burden. Intractable or refractory dyspnea is a substantial contributor to this suffering. As individuals continue to live longer, the number of "end-stage" COPD patients will increase. Their needs are similar to those of lung cancer patients but COPD patients are offered and use fewer palliative interventions. The reason for this is not clear but it may be due, at least in part, to a differential focus of the individuals caring for these two groups of patients. Palliative interventions for patients with advanced COPD have the potential to reduce the suffering caused by breathlessness. The goal of palliative interventions in "end-stage" disease is to decrease symptoms, and improve functional status and QOL.

In this paper we have outlined the interventions currently available for the global treatment of refractory dyspnea. Oral or parenteral opioids are beneficial with the most evidence available for morphine. Palliative oxygen may be beneficial for some patients; an "n of 1" trial is the best approach until further information is available. Anxiolytics and SSRIs have limited and sometimes conflicting data; they should be approached cautiously and with explicit expected outcomes until more information is available. Inhaled furosemide is an interesting potential intervention that needs more study. Heliox28 may or may not be beneficial but its use may be most limited by feasibility concerns. Nutrition needs further study, as does counseling, behavioral therapies, and breathlessness clinics for COPD. Instruction in positioning and PLB is a simple intervention with potential to be very effective but without prior systematic study. Maintaining physical activity, whether via a structured pulmonary rehabilitation program or via another intervention, remains an important intervention, albeit one that is less well studied in individuals with refractory breathlessness.

It is clear that there is more work to be done as many of the options have little or limited evidence to support their use. We have tried to identify areas that are currently under investigation as well as those that require further exploration. We are currently involved in a multi-center, randomized clinical trial investigating the role of palliative oxygen vs medical air in non-hypoxemic patients with intractable dyspnea. Additionally, there is an ongoing study evaluating varying doses of sustained-release morphine. A study of newer psychotropic agents is planned. Finally, non-pharmacologic interventions such as breathlessness clinics have proven benefit in lung cancer patients but need specific evaluation in COPD.

All of this translates to the needs for better palliative care for patients with advanced COPD and for the difficult problems that create suffering like refractory dyspnea. Whether this care is best provided by the patient's long-standing primary care provider or pulmonologist with or without specialist palliative care support or by primary palliative care teams who take over care remains to be seen. Hospices, inpatient palliative care units, and symptom management consults are also important supports for the care of the COPD patient with unrelenting dyspnea.
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